Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts
One of the strongest performing biopharmaceutical stocks this year is [...]
SanaCurrents Increasing Monthly Sentiment Report Frequency
SanaCurrents is increasing the frequency of its sentiment reports to subscribers [...]
ADMA New Catalysts For 2019 – Two PDUFA decisions on immunodeficiency therapies
SUMMARY SanaCurrents assigns a pivotal sentiment the FDA will approve [...]
Verona Pharma (VRNA) January 2019 Catalyst: Topline data for RPL554
SUMMARY Sana Currents assigns a pivotal sentiment that Verona Pharma [...]
Cara Therapeutics (CARA) Q1 2019 Catalyst: Phase III efficacy trial, KALM-2
SUMMARY Sana Currents assigns a pivotal sentiment that Cara Therapeutics [...]
Karyopharm’s Cancer Drug Achieves Impressive Results
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported impressive results on December 1, 2018 [...]
-
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – 3Q 2019 catalyst, CBD treatment for Fragile X GalleryZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – 3Q 2019 catalyst, CBD treatment for Fragile X
Bill Langbein, Health Care Equipment & Services, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – 3Q 2019 catalyst, CBD treatment for Fragile X
3Q ‘19 catalyst, CBD treatment for Fragile X SanaCurrents is [...]
-
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – December Catalyst, Lymphoma Phase IIb Trial GalleryKaryopharm Therapeutics Inc. (NASDAQ:KPTI) – December Catalyst, Lymphoma Phase IIb Trial
Bill Langbein, Health Care Equipment & Services, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – December Catalyst, Lymphoma Phase IIb Trial
December catalyst, lymphoma phase IIb trial SanaCurrents assigns a pivotal [...]
